Oxford BioDynamics
Market Cap
UK£75.0m
Last Updated
2021/01/22 20:22 UTC
Data Sources
Company Financials
Executive Summary
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use within the pharmaceutical and biotechnology industry primarily in the United Kingdom and Malaysia. More Details
Risk Analysis
Snowflake Analysis
Adequate balance sheet with weak fundamentals.
Share Price & News
How has Oxford BioDynamics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: OBD is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: OBD's weekly volatility (8%) has been stable over the past year.
Market Performance
7 Day Return
2.9%
OBD
0.7%
GB Life Sciences
-0.5%
GB Market
1 Year Return
-28.3%
OBD
15.1%
GB Life Sciences
-8.2%
GB Market
Return vs Industry: OBD underperformed the UK Life Sciences industry which returned 15.1% over the past year.
Return vs Market: OBD underperformed the UK Market which returned -7.7% over the past year.
Shareholder returns
| OBD | Industry | Market | |
|---|---|---|---|
| 7 Day | 2.9% | 0.7% | -0.5% |
| 30 Day | 0.3% | 4.5% | 3.0% |
| 90 Day | -12.2% | 33.1% | 14.1% |
| 1 Year | -28.3%-28.3% | 15.8%15.1% | -4.5%-8.2% |
| 3 Year | -57.5%-57.5% | 10.6%9.1% | 3.7%-9.0% |
| 5 Year | n/a | 65.6%62.7% | 42.1%14.4% |
Long-Term Price Volatility Vs. Market
How volatile is Oxford BioDynamics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
We're Not Very Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Rate4 months ago | Simply Wall St
Here's Why We're Not Too Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Situation9 months ago | Simply Wall St
Here's Why We're Not Too Worried About Oxford BioDynamics's (LON:OBD) Cash Burn SituationValuation
Is Oxford BioDynamics undervalued compared to its fair value and its price relative to the market?
4.79x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate OBD's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate OBD's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: OBD is unprofitable, so we can't compare its PE Ratio to the GB Life Sciences industry average.
PE vs Market: OBD is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OBD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OBD is overvalued based on its PB Ratio (4.8x) compared to the GB Life Sciences industry average (4.4x).
Next Steps
Future Growth
How is Oxford BioDynamics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
10.9%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Oxford BioDynamics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Next Steps
- Examine Oxford BioDynamics's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Oxford BioDynamics competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
Past Performance
How has Oxford BioDynamics performed over the past 5 years?
-12.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OBD is currently unprofitable.
Growing Profit Margin: OBD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: OBD is unprofitable, and losses have increased over the past 5 years at a rate of 12.3% per year.
Accelerating Growth: Unable to compare OBD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: OBD is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (31.5%).
Return on Equity
High ROE: OBD has a negative Return on Equity (-22.62%), as it is currently unprofitable.
Next Steps
Financial Health
How is Oxford BioDynamics's financial position?
Financial Position Analysis
Short Term Liabilities: OBD's short term assets (£15.2M) exceed its short term liabilities (£1.3M).
Long Term Liabilities: OBD's short term assets (£15.2M) exceed its long term liabilities (£625.0K).
Debt to Equity History and Analysis
Debt Level: OBD is debt free.
Reducing Debt: OBD has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if OBD has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if OBD has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Oxford BioDynamics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate OBD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate OBD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if OBD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if OBD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of OBD's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.6yrs
Average management tenure
CEO
Jon Anthony Burrows (57 yo)
0.83
Tenure
Dr. Jon Burrows, PhD, serves as the Chief Executive Officer at Oxford BioDynamics Plc since March 23, 2020. He has been President of Contract Services and Senior Vice President of Corporate Development at ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CFO & Director | 3.33yrs | UK£183.00k | 0.016% £ 12.2k | |
| Chief Scientific Officer & Director | 13.58yrs | UK£220.00k | 6.65% £ 5.0m | |
| Chief Executive Officer | 0.83yr | no data | no data | |
| Chief Technology Officer | 4.25yrs | no data | 6.3% £ 4.7m | |
| Group CDO | 1.58yrs | no data | no data | |
| Senior Vice President of Commercial Development | 3.83yrs | no data | no data | |
| Group CBO | 1yr | no data | no data | |
| Head of RA/QA | 1yr | no data | no data | |
| Company Secretary | no data | no data | no data | |
| Group Clinical Director | no data | no data | no data | |
| Clinical Director of Inflammation & Infection | no data | no data | no data | |
| Technical Consultant | no data | no data | no data |
1.6yrs
Average Tenure
57yo
Average Age
Experienced Management: OBD's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CFO & Director | 3.33yrs | UK£183.00k | 0.016% £ 12.2k | |
| Chief Scientific Officer & Director | 13.58yrs | UK£220.00k | 6.65% £ 5.0m | |
| Independent Non-Executive Director | 1.75yrs | UK£15.00k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Director | 4.25yrs | UK£1.00 | 0.47% £ 350.1k | |
| Member of Scientific Advisory Board | 1.25yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Non-Executive Chairman | 0.083yr | no data | no data |
2.5yrs
Average Tenure
59yo
Average Age
Experienced Board: OBD's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Oxford BioDynamics Plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Oxford BioDynamics Plc
- Ticker: OBD
- Exchange: AIM
- Founded: 2007
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£74.973m
- Shares outstanding: 92.56m
- Website: https://www.oxfordbiodynamics.com
Number of Employees
Location
- Oxford BioDynamics Plc
- 26 Beaumont Street
- Oxford
- Oxfordshire
- OX1 2NP
- United Kingdom
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| OBD | AIM (London Stock Exchange AIM Market) | Yes | Ordinary Shares | GB | GBP | Dec 2016 |
| OXBO.F | OTCPK (Pink Sheets LLC) | Yes | Ordinary Shares | US | USD | Dec 2016 |
Biography
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use within the pharmaceutical and biotechnology industry primarily in the United Kingdom and Malaysia. The company pro...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/22 20:22 |
| End of Day Share Price | 2021/01/22 00:00 |
| Earnings | 2020/03/31 |
| Annual Earnings | 2019/09/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.